Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: GlobeNewswire
– Patients Prescribed Bempedoic Acid, As Well As Bempedoic Acid and Ezetimibe, With or Without Other Lipid Lowering Therapies, Showed A One-Third Relative Reduction in Low-Density LDL-C From Pre-Treatment To 2-Years in the MILOS Study – – Real-World Results Demonstrated ~7-Fold Increase in Proportion of Patients Achieving LDL-C Goals When Treated With Bempedoic Acid or Bempedoic Acid and Ezetimibe – – Data From the MILOS German Cohort Showed Bempedoic Acid, Alone or With Ezetimibe, Was Effective and Had A Safety Profile in Real-World Settings Consistent With the CLEAR Outcomes Study – ANN ARBOR, Mich., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that its European partner, Daiichi Sankyo Europe (DSE), reported final 2-year follow-up data from the German cohort of the multinational, European observational MILOS study. The European study evaluated the real-world use of bempedoic acid, marketed as NILEMDO® in the EU and bempedoic acid and ezetimibe, mark
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 [Yahoo! Finance]Yahoo! Finance
- Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
ESPR
Earnings
- 11/7/24 - Miss
ESPR
Sec Filings
- 11/20/24 - Form 4
- 11/19/24 - Form 144
- 11/14/24 - Form SC
- ESPR's page on the SEC website